Eliminall 50 mg Spot-on Solution for Cats

Main information

  • Trade name:
  • Eliminall 50 mg Spot-on Solution for Cats
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Eliminall 50 mg Spot-on Solution for Cats
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • fipronil
  • Therapeutic area:
  • Cats

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0381/001
  • Authorization date:
  • 28-09-2011
  • EU code:
  • UK/V/0381/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:November2011

AN:00583/2010

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Eliminall50mgspot-onsolutionforcats

Exprolinevet50mgspot-onsolutionforcats

Eliminall50mgspot-onsolutionforcats(Austria,France,Germany,Greece,Italy,

Ireland,Luxemburg,Netherlands,UnitedKingdom,Portugal,Spain)

Exprolinevet50mgspot-onsolutionforcats(Norway,Denmark,Finland,Sweden)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

1pipette(0.5ml)contains:

Activesubstance:

Fipronil 50mg

Excipients:

Butylhydroxyanisole(E320) 0.10mg

Butylhydroxytoluene(E321) 0.05mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution.

Lightyellowtoyellow,clearliquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cats

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentandpreventionofflea(Ctenocephalidesspp.)andtick(Ixodesricinus)

infestationsincats.

Theproducthasapersistentinsecticidalefficacyforupto4weeksagainstfleas

(Ctenocephalidesspp.)andacaricidalefficacyforupto4weeksagainstIxodes

ricinusandforupto1weekagainstDermacentorreticulatusandRhipicephalus

sanguineus.Ifticksofsomespecies(DermacentorreticulatusandRhipicephalus

sanguineus)arepresentwhentheproductisapplied,alltheticksmaynotbekilled

withinthefirst48hoursbuttheymaybekilledwithinaweek.

Issued:November2011

AN:00583/2010

Page2of6

TheproductcanbeusedaspartofatreatmentstrategyforthecontrolofFlea

AllergyDermatitis(FAD),wherethishasbeenpreviouslydiagnosedbyaveterinary

surgeon.

4.3 Contraindications

Intheabsenceofavailabledata,theproductshouldnotbeusedonkittenslessthan

2monthsoldand/orweighinglessthan1kg.

Donotuseonsick(e.g.systemicdiseases,fever…)orconvalescentanimals.

Donotuseinrabbits,asadversereactionsandevendeathcouldoccur.

Donotuseincasesofhypersensitivitytotheactivesubstance,dimethylsulfoxideor

toanyofotherexcipients.

4.4 Specialwarningsforeachtargetspecies

Fleasfrompetsofteninfesttheanimal'sbasket,beddingandregularrestingareas

suchascarpetsandsoftfurnishingswhichshouldbetreated,incaseofmassive

infestationandatthebeginningofthecontrolmeasures,withasuitableinsecticide

andvacuumedregularly.

Theproductdoesnotpreventticksfromattachingtotheanimals.Iftheanimalhas

beentreatedpriortoexposuretotheticks,thetickwillbekilledinthefirst24-48

hoursafterattachment.Thiswillusuallybepriortoengorgement,minimisingbutnot

excludingtheriskoftransmissionofdiseases.Oncedead,tickswilloftendropoffthe

animal,butanyremainingticksmayberemovedwithagentlepull.

Nodataontheeffectofbathing/shampooingontheefficacyoftheproductincats

areavailable.However,basedoninformationavailablefordogs,weeklyimmersion

inwaterforoneminutereducestheperiodofpersistentinsecticidalefficacyagainst

fleasbyoneweek.

Foroptimumcontroloffleaproblemsinamulti-pethousehold,alldogsandcatsin

thehouseholdshouldbetreatedwithasuitableinsecticide.

WhenusedaspartofastrategyforthetreatmentofFleaAllergyDermatitis,monthly

applicationstotheallergicpatientandtoothercatsinthehouseholdare

recommended.

4.5 Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

Avoidcontactwiththeanimal'seyes.Inthecaseofaccidentaleyecontact,

immediatelyandthoroughlyflushtheeyeswithwater.

Donotapplytheproductonwoundsordamagedskin.

Animalsshouldbeweighedaccuratelypriortotreatment.

Issued:November2011

AN:00583/2010

Page3of6

ii)Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Thisproductcancausemucousmembraneandeyeirritation.Therefore,contact

betweentheproductandthemouthoreyesshouldbeavoided.

Inthecaseofaccidentaleyecontactimmediatelyandthoroughlyflushtheeyeswith

water.Ifeyeirritationpersistsseekmedicaladviceandshowthepackageleafletor

thelabeltothephysician.

Avoidcontentscomingintocontactwiththefingers.Ifthisoccurs,washoff

immediatelywithsoapandwater.

Washhandsafteruse.

Donotsmoke,drinkoreatduringapplication.

Peoplewithaknownhypersensitivitytofipronilordimethylsulfoxideorother

excipientsshouldavoidcontactwiththeveterinarymedicinalproduct.

Treatedanimalsshouldnotbehandleduntiltheapplicationsiteisdry,andchildren

shouldnotbeallowedtoplaywithtreatedanimalsuntiltheapplicationsiteisdry.Itis

thereforerecommendedthatanimalsarenottreatedduringtheday,butshouldbe

treatedduringtheearlyevening,andthatrecentlytreatedanimalsshouldnotbe

allowedtosleepwithowners,especiallychildren.

4.6 Adversereactions(frequencyandseriousness)

Iflickingoccurs,abriefperiodofhypersalivationmaybeobserved.

Amongtheextremelyraresuspectedadversereactions,transientcutaneous

reactionsontheapplicationsite(squamosis,localalopecia,pruritus,erythema)and

generalpruritusoralopeciahavebeenreportedafteruse.Exceptionally,

hypersalivation,reversibleneurologicsymptoms(hyperesthesia,depression,

nervoussymptoms)orvomitinghavebeenobservedafteruse.

4.7 Useduringpregnancy,lactationorlay

Laboratorystudiesusingfipronilhavenotshownanyevidenceofteratogenicor

embryotoxiceffects.Studieshavenotbeencarriedoutwiththisproductinpregnant

andlactatingqueens.Useinpregnancyandlactationonlyinaccordancewith

professionalveterinaryadviceandabenefit/riskassessment.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Routeofadministrationanddosage:

Externaluseonly.

Administerbytopicalapplicationtotheskin1pipetteof0.5mlperanimal.

Methodofadministration:

Removethepipettefromthetriplexbag.Holdthepipetteinanuprightposition,twist

andpullthecapoff.Turnthecaparoundandplacetheotherendofthecapbackon

thepipette.Pushandtwistthecaptobreaktheseal,thenremovethecapfromthe

Issued:November2011

AN:00583/2010

Page4of6

pipette.Spreadthehairsoftheanimalbetweentheshoulderbladestomaketheskin

visible.Placethetipofthepipetteontheskinandsqueezegentlytoemptyits

contentsontotheskin,preferablyattwospots,oneatthebaseoftheskullanda

second2-3cmsfurtherback.

Itisimportanttomakesurethattheproductisappliedtoanareawheretheanimal

cannotlickitoff,andtomakesurethatanimalsdonotlickeachotherfollowing

treatment.

Thehairshouldbepartedandtheproductappliedtotheskin.Temporarychangesto

thecoat(clumped/greasyhairand/ordepositsonthehair)maybenotedatthe

applicationsitewhichnormallydisappearswithin24hours.

Treatmentschedule:

Foroptimalcontroloffleaand/ortickinfestationthetreatmentschedulecanbe

basedonthelocalepidemiologicalsituation.

Intheabsenceofsafetystudies,theminimumtreatmentintervalis4weeks.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noadverseeffectswereobservedintargetanimalsafetystudiesincatsandkittens

aged2monthsandolderandweighingabout1kgtreatedonceamonthatfivetimes

therecommendeddoseforthreeconsecutivemonths.Theriskofexperiencing

adverseeffectsmayhoweverincreasewithoverdosing(seesection4.6).

4.11Withdrawalperiod

Notapplicable.

5.PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Ectoparasiticidesfortopicaluse.

ATCvetcode:QP53AX15

5.1 Pharmacodynamicproperties

Fipronilisaninsecticideandacaricidebelongingtothephenylpyrazolefamily.Itacts

byinhibitingtheGABAcomplex,bindingtothechloridechannelandthereby

blockingpre-andpost-synaptictransferofchlorideionsacrosscellmembranes.This

resultsinuncontrolledactivityofthecentralnervoussystemanddeathofinsectsor

acarids.

Issued:November2011

AN:00583/2010

Page5of6

Fipronilexhibitsaninsecticidalandacaricidalactivityagainstfleas(Ctenocephalides

spp.)andticks(Rhipicephalusspp.,Dermacentorspp.,Ixodesspp.includingIxodes

ricinus)inthecat.

Fleaswillbekilledwithin24hours.Tickswillusuallybekilledwithin48hafter

contactwithfipronil,howeverifticksofsomespecies(Dermacentorreticulatusand

Rhipicephalussanguineus)arepresentwhentheproductisapplied,alloftheticks

maynotbekilledwithinthefirst48hours,butmaybekilledwithinaweek.

5.2 Pharmacokineticproperties

Invitro,fipronilismainlymetabolisedwithsubcellularliverfractionstoitssulfone

derivative.However,thismaybeoflimitedrelevance“invivo”asfipronilispoorly

absorbedinthecat.Theconcentrationsoffipronilonthehairdecreasewithtime.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Butylhydroxyanisole(E320)

Butylhydroxytoluene(E321)

Polysorbate80

PovidoneK25

Dimethylsulfoxide

6.2 Incompatibilities

Noneknown.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:30months.

6.4. Specialprecautionsforstorage

Storeintheoriginalcontainerinordertoprotectfromlightandmoisture.

6.5 Natureandcompositionofimmediatepackaging

Whitepolypropylenepipetteclosedwitheitherapolyethyleneorpolyoxymethylene

cap.Each0.5mlpipetteispackedinapolyethyleneterephthalate/aluminium/low

densitypolyethylenetriplexbag.

Boxcontaining1,3,6,10,20or30pipettes.

Notallpacksizesmaybemarketed.

Issued:November2011

AN:00583/2010

Page6of6

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Fipronilmayadverselyaffectaquaticorganisms.Donotcontaminateponds,

waterwaysorditcheswiththeproductoremptycontainer.

7. MARKETINGAUTHORISATIONHOLDER

KRKA,d.d.,Novomesto

Šmarješkacesta6

8501Novomesto

Slovenia

8. MARKETINGAUTHORISATIONNUMBER

Vm01656/4029

9. DATEOFFIRSTAUTHORISATION

14November2011

10. DATEOFREVISIONOFTHETEXT

November2011

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

There are no news related to this product.